Klebsiella pneumoniae bioconjugate vaccine functional durability in mice

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Klebsiella pneumoniae is a major cause of hospital-acquired infections and neonatal sepsis globally.
• Increasing antibiotic resistance in K. pneumoniae complicates treatment options.
• No K. pneumoniae vaccine is currently approved for clinical use.

Purpose of the Study:

• To assess the durability and long-term functionality of antibodies induced by two K. pneumoniae bioconjugate vaccines.
• To evaluate the potential of bioconjugate vaccines in eliciting sustained protective immune responses against K. pneumoniae.

Main Methods:

• Testing antibody durability and functionality in mice up to six months post-vaccination.
• Measuring IgG titers and assessing serum bactericidal activity.
• Evaluating survival rates in a murine bacteremia challenge model.

Main Results:

• Both vaccine candidates induced durable antibodies in mice for six months, maintaining significant IgG titers.
• Antibodies targeting K. pneumoniae capsular type K2 demonstrated sustained functionality.
• K2 antibodies showed significant serum bactericidal activity and improved survival in a challenge model.

Conclusions:

• Bioconjugate vaccines can induce durable antibody responses against K. pneumoniae.
• Sustained antibody functionality is crucial for long-term protection.
• These findings support the potential of bioconjugate vaccines for clinical application against K. pneumoniae infections.